IL-2 gene therapy for chronic hepatitis B virus infection

Informacje na temat projektu

2LIVEr

Identyfikator umowy o grant: 957502

DOI

10.3030/957502

Projekt został zamknięty

Data podpisania przez KE 25 Czerwca 2020

Data rozpoczęcia 1 Lipca 2020

Data zakończenia 30 Czerwca 2022

Finansowanie w ramach

• EXCELLENT SCIENCE - European Research Council (ERC)

Koszt całkowity

Brak danych

Wkład UE

€ 150 000,00

Koordynowany przez

OSPEDALE SAN RAFFAELE SRL
Italy

Periodic Reporting for period 1 - 2LIVEr (IL-2 gene therapy for chronic hepatitis B virus infection)

Okres sprawozdawczy: 2020-07-01 do 2022-06-30

Podsumowanie kontekstu i ogólnych celów projektu

Approximately two billion people worldwide have evidence of past or present infection with hepatitis B virus (HBV), and 350-400 million individuals are chronic carriers (i.e. positive for hepatitis B surface antigen HBsAg). Conventional treatments are based on antiretroviral drugs that require lifelong treatment. Current treatments for chronic HBV infection (NUCs and IFN-a) improve the quality of life and survival of infected patients, but their effects are not sustained (NUC treatment needs to be maintained for life and IFN-a achieves stable HBV suppression in 5-7% of patients). However, a definitive treatment for HBV eradication is not yet available on the market. The global chronic hepatitis B therapeutics market is expected to reach a value of $3 billion by 2024. Activating the immunological mechanisms that allow spontaneous HBV resolution is a sensible strategy for the treatment of chronic HBV infection. Within this project, we undertook to develop an innovative treatment consisting in a single-dose gene therapy-based approach that, when combined with existing and/or upcoming antivirals, aims at inducing a functional cure against chronic hepatitis B.